
From the Desk of Dr. Z: AgelessRx Co-founder and former Chief Medical Officer, Dr. Sajad Zalzala, offers his insightful perspective on topics related to longevity. With a wealth of experience and a deep-seated passion for disease prevention and extending healthy lifespans, Dr. Z is dedicated to sharing his knowledge on the secrets to longevity. Today, he shares his knowledge on combining LDN with Microdosing GLP-1.
Here’s what we’ll cover in this blog post:
- Combining LDN with Microdosing GLP-1
- Potential combined benefits
- When LDN alone isn’t enough
As interest in healthspan optimization grows, innovative therapies are emerging to address the underlying mechanisms of aging and chronic conditions. Two promising candidates—Low Dose Naltrexone (LDN) and Microdosing GLP-1—have garnered attention for their ability to modulate inflammation, metabolic health, and immune function.
While each therapy offers unique benefits, combining them may provide a synergistic approach, particularly for patients who have not experienced optimal outcomes with LDN alone.
LDN: A Versatile Gerotherapeutic
Low Dose Naltrexone works primarily through its immunomodulatory and anti-inflammatory effects:
- Mechanism of Action (MOA):
- Blocks toll-like receptor 4 (TLR4), reducing pro-inflammatory cytokine release (e.g., IL-6)
- Increases endorphin levels, promoting immune balance and cellular repair
- Enhances mitochondrial function by reducing oxidative stress
While many patients respond well to LDN, some may require additional support to address complex metabolic and inflammatory issues.
Why Combine LDN and Microdosing GLP-1?
Combining these therapies may amplify their individual benefits by targeting complementary pathways:
- Enhanced inflammation modulation
LDN suppresses cytokines like IL-6, while GLP-1s may reduce broader inflammatory markers and oxidative stress. - Metabolic synergy
GLP-1 effects on insulin sensitivity and appetite regulation may complement LDN’s ability to improve mitochondrial function and cellular repair. - Immune optimization
LDN balances the immune response, while GLP-1s may support systemic health, reducing the burden of chronic inflammation on the immune system. - Neuroprotection
Both LDN and GLP-1 may reduce neuroinflammation and oxidative stress, potentially mitigating risks of cognitive decline and neurodegenerative diseases.
When LDN Alone May Not Be Enough
Some patients may experience suboptimal results with LDN alone, due to:
- Persistent metabolic dysregulation (like insulin resistance)
- Chronic inflammatory states resistant to LDN’s immunomodulatory effects
- Co-existing conditions such as mild cognitive impairment or mood disorders
- Limitations with existing medications (like tramadol or other opiates) that excludes from LDN therapy, but not Microdosing GLP-1
In these cases, adding Microdosing GLP-1 may enhance outcomes by addressing metabolic and systemic inflammation more comprehensively.
If you’d like to learn more for your own health journey, consult your AgelessRx provider or speak with your healthcare provider directly.
Note: The above statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.